EP1458252B1 - Tobacco and/or tobacco in combination with tobacco substitute composition for use as a snuff in the oral cavity - Google Patents
Tobacco and/or tobacco in combination with tobacco substitute composition for use as a snuff in the oral cavity Download PDFInfo
- Publication number
- EP1458252B1 EP1458252B1 EP02795287A EP02795287A EP1458252B1 EP 1458252 B1 EP1458252 B1 EP 1458252B1 EP 02795287 A EP02795287 A EP 02795287A EP 02795287 A EP02795287 A EP 02795287A EP 1458252 B1 EP1458252 B1 EP 1458252B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- nicotine
- tobacco
- composition according
- release
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 136
- 241000208125 Nicotiana Species 0.000 title claims abstract description 119
- 235000002637 Nicotiana tabacum Nutrition 0.000 title claims abstract description 119
- 210000000214 mouth Anatomy 0.000 title claims abstract description 25
- 239000012528 membrane Substances 0.000 claims abstract description 190
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 155
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 136
- 229960002715 nicotine Drugs 0.000 claims abstract description 136
- 239000000463 material Substances 0.000 claims abstract description 46
- 239000000126 substance Substances 0.000 claims abstract description 42
- 230000000694 effects Effects 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000000391 smoking effect Effects 0.000 claims abstract description 12
- 206010057852 Nicotine dependence Diseases 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims description 33
- 239000012453 solvate Substances 0.000 claims description 33
- -1 propylcellulose Polymers 0.000 claims description 32
- 230000002209 hydrophobic effect Effects 0.000 claims description 18
- 229920002678 cellulose Chemical class 0.000 claims description 10
- 239000001913 cellulose Chemical class 0.000 claims description 10
- 229920002301 cellulose acetate Polymers 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 239000004698 Polyethylene Substances 0.000 claims description 7
- 239000012535 impurity Substances 0.000 claims description 7
- 229920000573 polyethylene Polymers 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000035699 permeability Effects 0.000 claims description 5
- MXYUKLILVYORSK-UHFFFAOYSA-N (+/-)-allo-lobeline Natural products C1CCC(CC(=O)C=2C=CC=CC=2)N(C)C1CC(O)C1=CC=CC=C1 MXYUKLILVYORSK-UHFFFAOYSA-N 0.000 claims description 3
- MXYUKLILVYORSK-HBMCJLEFSA-N (-)-lobeline Chemical compound C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 MXYUKLILVYORSK-HBMCJLEFSA-N 0.000 claims description 3
- MTXSIJUGVMTTMU-JTQLQIEISA-N (S)-anabasine Chemical compound N1CCCC[C@H]1C1=CC=CN=C1 MTXSIJUGVMTTMU-JTQLQIEISA-N 0.000 claims description 3
- MYKUKUCHPMASKF-VIFPVBQESA-N (S)-nornicotine Chemical compound C1CCN[C@@H]1C1=CC=CN=C1 MYKUKUCHPMASKF-VIFPVBQESA-N 0.000 claims description 3
- QLDPCHZQQIASHX-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.CN1CCCC1C1=CC=CN=C1 QLDPCHZQQIASHX-UHFFFAOYSA-N 0.000 claims description 3
- AIBWPBUAKCMKNS-PPHPATTJSA-N 2-hydroxybenzoic acid;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)C1=CC=CC=C1O.CN1CCC[C@H]1C1=CC=CN=C1 AIBWPBUAKCMKNS-PPHPATTJSA-N 0.000 claims description 3
- WHAIHNKQZOMXJJ-NSHDSACASA-N 3-[(2s)-1-methylpiperidin-2-yl]pyridine Chemical compound CN1CCCC[C@H]1C1=CC=CN=C1 WHAIHNKQZOMXJJ-NSHDSACASA-N 0.000 claims description 3
- MQWJVKLIBZWVEL-XRIOVQLTSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;dihydrochloride Chemical compound Cl.Cl.CN1CCC[C@H]1C1=CC=CN=C1 MQWJVKLIBZWVEL-XRIOVQLTSA-N 0.000 claims description 3
- HDJBTCAJIMNXEW-PPHPATTJSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;hydrochloride Chemical compound Cl.CN1CCC[C@H]1C1=CC=CN=C1 HDJBTCAJIMNXEW-PPHPATTJSA-N 0.000 claims description 3
- IECQULMJVNSKDB-RCWTXCDDSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;sulfuric acid Chemical compound OS(O)(=O)=O.CN1CCC[C@H]1C1=CC=CN=C1.CN1CCC[C@H]1C1=CC=CN=C1 IECQULMJVNSKDB-RCWTXCDDSA-N 0.000 claims description 3
- 244000043261 Hevea brasiliensis Species 0.000 claims description 3
- 244000061176 Nicotiana tabacum Species 0.000 claims description 3
- MYKUKUCHPMASKF-UHFFFAOYSA-N Nornicotine Natural products C1CCNC1C1=CC=CN=C1 MYKUKUCHPMASKF-UHFFFAOYSA-N 0.000 claims description 3
- 229930014345 anabasine Natural products 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 229960002339 lobeline Drugs 0.000 claims description 3
- 229930013610 lobeline Natural products 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229920003052 natural elastomer Polymers 0.000 claims description 3
- 229920001194 natural rubber Polymers 0.000 claims description 3
- 229940069688 nicotine bitartrate Drugs 0.000 claims description 3
- LDMPZNTVIGIREC-ZGPNLCEMSA-N nicotine bitartrate Chemical compound O.O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 LDMPZNTVIGIREC-ZGPNLCEMSA-N 0.000 claims description 3
- 239000000779 smoke Substances 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 235000019640 taste Nutrition 0.000 claims description 3
- BRTHFWPGJMGHIV-UHFFFAOYSA-L zinc;3-(1-methylpyrrolidin-2-yl)pyridine;dichloride;hydrate Chemical compound O.[Cl-].[Cl-].[Zn+2].CN1CCCC1C1=CC=CN=C1 BRTHFWPGJMGHIV-UHFFFAOYSA-L 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 241000208134 Nicotiana rustica Species 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 241000208292 Solanaceae Species 0.000 claims description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000012676 herbal extract Substances 0.000 claims description 2
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 2
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 239000004800 polyvinyl chloride Substances 0.000 claims description 2
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 241000196324 Embryophyta Species 0.000 claims 1
- 229920003266 Leaf® Polymers 0.000 claims 1
- 235000019568 aromas Nutrition 0.000 claims 1
- 229940112822 chewing gum Drugs 0.000 claims 1
- 235000015218 chewing gum Nutrition 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 235000019504 cigarettes Nutrition 0.000 abstract description 7
- 235000019505 tobacco product Nutrition 0.000 abstract description 6
- 235000019506 cigar Nutrition 0.000 abstract description 4
- 210000004379 membrane Anatomy 0.000 description 166
- 238000009792 diffusion process Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 9
- 230000004907 flux Effects 0.000 description 8
- 239000011148 porous material Substances 0.000 description 7
- 239000004627 regenerated cellulose Substances 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002211 ultraviolet spectrum Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 150000004005 nitrosamines Chemical class 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B13/00—Tobacco for pipes, for cigars, e.g. cigar inserts, or for cigarettes; Chewing tobacco; Snuff
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
Definitions
- the present invention relates to a novel composition for the use as snuff in the oral cavity, the composition comprising tobacco and/or tobacco in combination with a tobacco substitute encapsulated in a membrane material comprising one or more membranes at least one of which being water permeable and water-insoluble.
- a novel composition enables a selective release of e.g. nicotine while it at the same time reduces the release of substances, which normally lead to unwanted side effects.
- the novel compositions may be used as a healthier alternative to snuff and other tobacco products such as, e.g., cigarettes, cigars and pipe.
- the invention also relates to methods for giving up smoking, reducing nicotine craving, reducing side effects normally related to smoking and snuffing of tobacco as well to a method for the preparation of a composition according to the invention.
- various buffer systems may be added, e.g. carbonates.
- the moist snuff is either packed loosely, as bulk in a box or as single doses in small non-woven bags. A number of the filled and sealed bags are then packed in a box.
- the moist snuff as a single dose has become popular due to the ease of use compared to the bulk product.
- the popularity of moist snuff is most probably due to its pharmacological nicotine absorption profile.
- the dose of nicotine and speed of absorption is approximately 10 ng per ml over 10 minutes.
- Plasma nicotine concentrations rapidly increase within the first few minutes of the use of snuff and reach levels comparable to those obtained from smoking cigarettes within 30 min of use. Measurements of plasma nicotine concentrations after a single day of moist snuff consumption also yielded levels similar to cigarette use.
- the kinetics is slightly slower compared to the kinetics when smoking tobacco, such as e.g. cigarettes and cigars; however, the overall amount of nicotine absorbed is higher when snuff is employed.
- snuff is the vast number of compounds, more or less harmful to the body, e.g. different tobacco-specific nitrosamines, which are compounds known to cause different diseases such as, e.g., gastro-intestinal disorders and cancer.
- US 4,141,369 describes a method of inhaling the nicotine from tobacco without combustion of the tobacco.
- Another way of avoiding the harmful substances contained in tobacco is to substitute tobacco with nicotine.
- Various devices have also be constructed in order to deliver nicotine from a tobacco composition placed in the oral cavity:
- US 5,346,734 describes a perforated latex oral pouch for loose, moist snuff, the pouch serving as a barrier to avoid direct physical contact between the tobacco product and the gum.
- the pouch has to be filled by the user, cut to fit the mouth cavity of the user and is re-usable.
- US 6,162,516 describes a shield, which also has to be filled with snuff by the user, the shield acting as a barrier to reduce tobacco contact with the sensitive inner cheek lining and gum surfaces while using snuff.
- the present invention provides a composition wherein the release of nicotine from snuff can be designed freely, even though the release of unwanted and harmful substances from the tobacco is dramatically reduced.
- the present invention provides a composition for use in the oral cavity comprising tobacco and/or tobacco in combination with a tobacco substitute encapsulated in a membrane material comprising one or more membranes at least one of which being water permeable and water-insoluble.
- the gist of the invention is the employment of a membrane material which makes it possible to deliver nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof in a predetermined manner and - at the same time - has the properties of withholding the substances which are unwanted to such a degree that the side-effects normally observed in connection with the use of snuff in the oral cavity are dramatically reduced.
- the tobacco used in the novel snuff composition according to the invention may be natural tobacco leaves in order to preserve the authentic taste and feeling of tobacco.
- the tobacco plant belongs to the family Solanaceae and the genus Nicotiana. More than 60 tobacco species exists, the most commonly used in smoking or snuffing tobacco products being Nicotiana tabacum and Nicotiana rustica.
- To manufacture moist snuff the tobacco, which typically has a content of from about 1% to 8% nicotine, is dried, milled and mixed with a fermentative solution. The mixture is then fermented, typically for 5 days to 4 weeks at elevated temperature. After this the tobacco mass is mixed with a suitable buffer, such as e.g.
- the water content in the final product may lie in the range from about 10 % to about 60 %.
- additional compounds may be added, such as e.g. sweeteners, aroma substances and other taste additives, detergents and preservative, release modifying agents, and other liquids such as oil, organic solvents and herbal extracts.
- the natural fermented tobacco may be partly substituted with a tobacco substitute, such as, e.g., nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof selected from the group consisting of nor-nicotine, lobeline, methylanabasine, anabasine, nicotine hydrochloride, nicotine dihydrochloride, nicotine sulphate, nicotine monotartrate, nicotine bitartrate, nicotine salicylate or nicotine zinc chloride monohydrate.
- a tobacco substitute such as, e.g., nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof selected from the group consisting of nor-nicotine, lobeline, methylanabasine, anabasine, nicotine hydrochloride, nicotine dihydrochloride, nicotine sulphate, nicotine monotartrate, nicotine bitartrate, nicotine salicylate or nicotine zinc chloride monohydrate.
- some additional filler may be added, such as, e.g., non-digestible fibers.
- the tobacco and/or tobacco substitute may preferably have a content of nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof, from about 0% w/w to about 30% w/w such as, e.g., from about 0.5% w/w to about 25% w/w, from about 0.1% w/w to about 20% w/w, from about 0.1% w/w to about 15% w/w, from about 0.1% w/w to about 10% w/w, from about 0.1% w/w to about 9% w/w or from about 0.1% w/w to about 8% w/w.
- a content of nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof from about 0% w/w to about 30% w/w such as, e.g., from about 0.5% w/w to about 25% w/w, from about 0.1% w/w to about 20% w/w, from about 0.1% w/w to about 15%
- the tobacco and/or tobacco substitute is enclosed in a membrane material.
- the membrane material may comprise one or more membranes.
- membrane describes a thin polymeric film having natural pores and acting as a selective permeability barrier. The term does not include papermade material or polymeric materials in which not-naturally occurring openings have been made.
- At least one of the membranes may be water-insoluble to prevent spreading of the snuff in the oral cavity, and to maintain the beneficial properties of the selective membrane material during use, with respect to the withholding of unwanted substances.
- At least one of the membranes may be water permeable in order to allow water to diffuse into the encapsulated tobacco and/or tobacco substitute and to allow e.g. nicotine to diffuse through the polymeric membrane material and thus becoming available for absorption.
- the membranes may have a predominantly hydrophilic or hydrophobic nature.
- the hydrophilic or hydrophobic nature of the membrane has an effect on the release of substances such as, e.g., nicotine through the membrane, since the flow of substances through the membrane is dependent on the ability of the membrane to hydrate, e.g. create hydro-channels through the membrane. These hydro-channels are a prerequisite for molecular transport when dry polymeric membranes are used.
- the flow of hydrophilic substances through a hydrophobic membrane is slower compared to a hydrophilic membrane. This is probably due to less swelling of the hydrophobic membrane pores, i.e. in the hydrophobic membranes nicotine diffusion occurs through well-organized polymeric material and hydrophobic organized water.
- One or more of the membranes used for making the composition may be a synthetic or semi-synthetic membrane.
- a synthetic or semi-synthetic membrane As is given some examples of natural, synthetic and semi-synthetic hydrophilic and hydrophobic membranes, which may be used in a novel snuff composition according to the invention.
- membranes are membranes made of cellulose acetate and derivates thereof, carboxymethyl cellulose membranes, polycellulose ester membranes, other cellulose derivatives such as, e.g., ethylcellulose, propylcellulose, polyethylene membranes, polypropylene membranes, polystyrene membranes, polyvinyl chloride membranes, polyvinyl acetate membranes, membranes made of polymers of methacrylates and acrylates, natural rubber membranes, polycarbonate membranes, polyethylene terephthalate membranes, polyester membranes, polyamide membranes and nylon membranes.
- cellulose acetate and derivates thereof such as, e.g., ethylcellulose, propylcellulose, polyethylene membranes, polypropylene membranes, polystyrene membranes, polyvinyl chloride membranes, polyvinyl acetate membranes, membranes made of polymers of methacrylates and acrylates, natural rubber membranes, polycarbonate membranes, polyethylene tere
- At least the outer membrane in the membrane material enclosing the tobacco and/or tobacco substitute may be made from a biocompatible and physiologically acceptable polymeric material, since the novel snuff composition has to be placed close to or in contact with the mucous membrane in the oral cavity during use.
- At least one of the membranes in a membrane material may be surface treated with e.g. polycarbophils to obtain a bioadhesiveness of the novel snuff composition in the oral cavity.
- the molecular weight cut off of the membrane material used in the novel snuff composition may be varied to obtain a desired release of nicotine and other substances through the membrane material.
- the molecular weight cut-off of a membrane is defined as the molecular weight of the smallest molecule of which 90 % will be prevented from permeating the membrane.
- the exact permeability of a molecule is dependent on the shape, the degree of hydration and the charge of the molecule.
- At least one of the membranes comprising the membrane material may have a molecular weight cut-off from about 500 to about 40,000 such as, e.g., from about 500 to about 5,000, from about 800 to about 4,000, from about 1,000 to about 3,500; or from about 2,000 to about 40,000, from about 3,000 to about 30,000, from about 5,000 to about 25,000, from about 7,500 to about 20,000 or from about 10,000 to about 20,000.
- a molecular weight cut-off from about 500 to about 40,000 such as, e.g., from about 500 to about 5,000, from about 800 to about 4,000, from about 1,000 to about 3,500; or from about 2,000 to about 40,000, from about 3,000 to about 30,000, from about 5,000 to about 25,000, from about 7,500 to about 20,000 or from about 10,000 to about 20,000.
- the release of nicotine and/or other substances through the membrane material is also dependent on the thickness of the membrane materiel.
- the diffusion process of molecules through the membrane is decreased when the membrane thickness is increased and vice versa.
- the thickness of the membrane material may be varied in respect of obtaining a desired release of nicotine and other substances through the membrane material.
- the lower limit for the membrane material thickness is determined by what is possible from a practical point of view, and the upper value is restricted by what will allow a comfortable fit of the novel snuff composition in the oral cavity of the user.
- At least one of the membranes comprising the membrane material may have a thickness of from 2 to about 200 ⁇ m such as, e.g., from about 5 to about 100 ⁇ m, from about 7.5 to about 50 ⁇ m, from about 7.5 to about 40 ⁇ m, from about 7.5 to about 35 ⁇ m, from about 7.5 to about 30 ⁇ m or from about 7.5 to about 25 ⁇ m.
- nicotine or a nicotine derivative, analog, salt, solvate or a mixture thereof, selected from the group consisting of nor-nicotine, lobeline, methylanabasine, anabasine, nicotine hydrochloride, nicotine dihydrochloride, nicotine sulphate, nicotine monotartrate, nicotine bitartrate, nicotine salicylate or nicotine zinc chloride monohydrate, has to be released from the composition.
- the release profile may be designed with respect to the rate and amount of nicotine and unwanted substances released by the membrane.
- the release of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from a novel snuff composition may be designed to be released in a sufficient amount and/or a sufficient rate to enable a desired effect and on the other hand be designed to retain substances, which normally give rise to side-effects, such as, e.g., nitrosamines, and/or to release such substances in a substantially low amount and/or at a substantially slow rate.
- the Impurity Index- IPI - is introduced.
- the IPI is calculated from the UV-spectra recorded from 200 nm to 900 nm as described in Example 2, and is defined as the ratio of the sum of peak heights other than that of nicotine (i.e. thus including unwanted and harmful substances) to the peak height of nicotine. In other words, a low IPI reflects that a large amount of nicotine is released through the membrane compared to the amount of unwanted substances.
- the impurity index IPI is at the most 3.0 such as, e.g. at the most 2.75, at the most 2.5, at the most 2.0, at the most 1.75, at the most 1.5, at the most 1.5 or at the most 1.4 when measured after 90 min.
- the release profile of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from the invention could e.g., be fast and equivalent to the release of nicotine from the commercially available moist snuff, while maintaining a low IPI value, i.e. limiting the release of unwanted substances.
- a composition according to the invention can be designed to release nicotine and/or a derivative, analog, salt, solvate or mixture thereof in a controlled manner such as, e.g., fast (faster than from the reference product employed in the examples herein), relatively fast (i.e. similar or almost similar to the reference product employed in the examples herein), delayed (i.e. with a lag time in which period no nicotine is released followed by a release of nicotine), prolonged or sustained (i.e. a relatively slower release than the reference product to avoid any peak concentration and to obtain a relatively constant plasma concentration of nicotine after application).
- fast fast
- relatively fast i.e. similar or almost similar to the reference product employed in the examples herein
- delayed i.e. with a lag time in which period no nicotine is released followed by a release of nicotine
- prolonged or sustained i.e. a relatively slower release than the reference product to avoid any peak concentration and to obtain a relatively constant plasma concentration of nicotine after application.
- the release of nicotine or a derivative, analog, salt, solvate or a mixture thereof may be delayed compared to the commercially available moist snuff, to mimic the effect of nicotine replacement products such as, e.g., patches.
- the release of nicotine or a derivative, analog, salt, solvate or a mixture thereof may be determined by the release test described in Example 1, but other suitable methods for determining the release of nicotine may also be used, i.e. the embodiments of the invention described below referrer to Example 1 without limiting the relevant release tests to the one described in Example 1.
- the tobacco and/or tobacco in combination with a tobacco substitute composition may be designed so that at least about 50% w/w of the total content of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof is released within at the most 60 min when subject to the release test described in Example 1 below.
- the tobacco and/or tobacco substitute composition may be designed so that at the most 25% w/w of the total content of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof is released within at the most 60 min when subject to the release test described in Example 1 below.
- the tobacco and/or tobacco substitute composition may be designed so that at least about 50% w/w of the total content of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof is released within at the most 120 min when subject to the release test described in Example 1 below.
- release profiles for compositions according to the invention are described as %w/w released of total nicotine content as a function of time, measured at 0, 3, 30, 90 and 180 minutes.
- the release profiles according to the invention also includes profiles described by only one or any combination of the values below, i.e. a release profile according to the invention could be defined by e.g. the %w/w release of nicotine at 3 minutes and 90 min, or at 3 and 90 and 180 minutes, or at 90 and 180 minutes or any possible combination of the values shown below.
- a composition according to the invention is suitable designed to release nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from the tobacco or tobacco in combination with the tobacco substitute with the following characteristics: time (min) % w/w released of total nicotine content 0 from about 0 to about 20 such as, e.g., from about 0 to about 15 or from about 0 to about 10, 3 from about 0 to about 40 such as, e.g., from about 0 to about 35, from about 0 to about 30, from about 0 to about 25, from about 0 to about 20, 30 from about 2 to about 100, such as, e.g., from about 2 to about 90, from about 2 to about 80, from about 2 to about 70, from about 2 to about 65, from about 2 to about 60, from about 5 to about 60, from about 5 to about 55, from about 7.5 to about 55 or from about 10 to about 50, op til 100 90 from about 10 to about 100 such as, e.g., from about 10 to about 95, from about
- a composition according to the invention releases nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from the tobacco or the tobacco in combination with a tobacco substitute with the following release profile characteristics: time (min) % w/w released of total nicotine content 0 from about 0 to about 15 3 from about 1 to about 25 30 from about 7.5 to about 55 90 from about 35 to about 80 180 from about 65 to about 100 and the release is determined as described herein in Example 1.
- a composition according to the invention releases, nicotine and/or derivative, analog, salt or solvate thereof from the tobacco or the tobacco in combination with a tobacco substitute with the following release profile characteristics: time (min) % w/w released of total nicotine content 0 from about 0 to about 10 3 from about 1 to about 20 30 from about 10 to about 50 90 from about 40 to about 90 180 from about 70 to about 100 and the release is determined as described herein in Example 1.
- a composition according to the invention releases nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from the tobacco or the tobacco in combination with a tobacco substitute with the following release profile characteristics: time (min) % w/w released of total nicotine content 0 from about 0 to about 10 3 from about 1 to about 20 30 from about 30 to about 50 90 from about 65 to about 90 and the release is determined as described herein in Example 1.
- membrane material properties such as hydrophobicity, hydrophilicity, molecular weight cut-off and membrane thickness may be used in designing a desired release profile for nicotine or a derivative, analog, salt, solvate or mixture thereof.
- a multi-layer membrane is e.g. designed to contain one membrane material being hydrophilic and a second membrane material being lipophilic. Both membrane components are chosen in such a manner that the membrane material has a molecular cut off large enough for the relatively small nicotine molecule to pass through with ease.
- amphiphilic nature of nicotine enables it to pass both hydrophilic and hydrophobic materials while a majority of both hydrophilic and lipophilic unwanted and harmful substances are excluded from permeation through the membrane material.
- Many other combinations of different types of membranes are of course possible and based on the disclosure herein a skilled person will know how to chose different membranes in order to obtain a suitable release.
- compositions according to the invention are a composition wherein the membrane material is a bi-layer membrane with one membrane being preferentially hydrophilic and one membrane being predominantly hydrophobic. Both membranes possess high permeability to nicotine while maintaining low aqueous pore diffusion.
- the release profile of nicotine could either be identical to the release profile of original snuff or it could be designed to have a prolonged or sustained release. The unwanted and harmful substances from the tobacco should substantially be maintained inside the membrane.
- a composition according to the invention may attain all possible sizes and shapes, such as, e.g. round, circular, oblong, elliptical, square, rectangular or trapezoidal.
- the shape and/or size chosen may be such as to allow a comfortable fit in the oral cavity.
- the location in the oral cavity of a composition according to the invention may be centered or to the sides under the upper front lip, centered or to the sides under the lower front lip, under the tongue or in the cheeks.
- the invention also relates to use of a composition according to the invention as a smoke substitute and it can be used by persons who suffer from nicotine craving or who want to give up or reduce smoking.
- the content of tobacco and/or a tobacco substitute is adjusted to the individual purposes and it is possible to design a kit comprising compositions according to the invention with different concentrations of tobacco and/or a tobacco substitute.
- Such compositions in a kit could e.g. contain compositions with a decreasing content of tobacco or nicotine.
- Membranes made of regenerated cellulose acetate dialysis tubing with varying MW cut-off together with vinyl and polyethylene membranes with various thicknesses were tested with respect to the diffusion profiles over the membranes of nicotine released from tobacco.
- snuff tobacco SVENSKT SNUS, GOTHIATEK, General
- PBS phosphate buffered saline according to Ph. Eur.
- PBS with a pH of 6.6 was placed in the receiver chamber.
- the cells of the diffusion chamber were kept at a temperature of 37°C ⁇ 0.5°C by attachment to a water bath. The temperature control was made in order to simulate the environment of the oral cavity.
- Diffusion profiles were constructed by sampling from the receiver chamber at 0, 3, 30, 60, 90, 120, (110 min for the polyethylene membrane) and 180 min after the start of the diffusion experiment.
- the concentration of nicotine in the receiver chamber was measured by HPLC, using a C-18, 5 ⁇ , 4.5 mm x 15 cm column, employing a mobile phase consisting of 70 % v/v 0.1 M phosphate buffer (pH 4.5), 30 % acetonitrile, and 2.3 g sodium dodecyl sulphate/liter at a flow rate of 1 ml /min and a temperature of 40°C.
- the sample volume was 10 ⁇ l and detection was carried out using a UV-detector running at 260 nm.
- the membranes used were regenerated cellulose acetate dialysis tubing with varying MW cut-off and vinyl and polyethylene membranes with varying thickness.
- Table I shows a comparison of the release profile of nicotine for a commercial non-woven snuff-bag, and a piece of filter paper used as reference in the experiments. The measurements were performed as described above, and the results are the mean of 2 single runs. Table I. Comparison of the nicotine release profile for a commercial non-woven filter and a reference paper filter Filter type Nicotine released (mg/ml) 15 sec. 30 min. 60 min. 90 min. Reference paper filter 11.5 64.4 92.0 202.4 Commercial non-woven filter 9.4 65.8 90.1 205.5
- Hydrophobic membranes e.g. vinyl and polyethylene membranes
- the slower profile is probably due to less swelling of the hydrophobic membrane pores, i.e. in the hydrophobic membranes nicotine diffusion occurs through well-organized polymeric material and hydrophobic organized water rather than through aqueous pores.
- Figure 1 shows that the release of nicotine over a hydrophilic membrane made of regenerated cellulose acetate dialysis tubing is high and close to the nicotine release over the reference filter paper.
- Figure 1 also shows that the physical properties, i.e. the molecular weight cut-off and thickness of the hydrophilic membrane, affect the permeability of nicotine as stated below.
- a membrane with a relatively small molecular weight cut-off tends to have a sigmoid release profile for nicotine.
- a considerable lag time is expected before the nicotine starts to permeate the membrane, even though the size of a nicotine molecule is significantly smaller than the molecular weight cut-off of 3,500.
- a membrane with a higher molecular weight cut-off e.g. a molecular weight cut-off of 13,000, seems to have a release profile for nicotine that is very close to the release profile for nicotine of the reference filter paper.
- This difference may be due to a much lower aqueous mobility of nicotine in the membrane with a molecular weight cut-off of 3,500, compared to the membrane with a molecular weight cut-off of 13,000.
- Figure 1 also shows that when the thickness of a membrane increases, then the flux of nicotine through the membrane decreases.
- Example 1 shows that it is possible to design a polymeric membrane which gives rise to a release profile of nicotine from moist tobacco through the membrane very similar to the release profile through a commercial non-woven snuff-bag, i.e. with respect to the shape of the profile and the individual release data (time, percentage released). Especially, it seems that a hydrophilic membrane material is suitable. Furthermore, the release profile is dependent of the molecular weight cut-off of the membrane, the thickness of the membrane and of the membrane material itself.
- Example 1 also shows that some hydrophobic membranes, e.g. vinyl and polyethylene membranes, have a slower nicotine release profile compared to the hydrophilic membranes.
- hydrophobic membranes e.g. vinyl and polyethylene membranes
- membranes which enable a specific release of nicotine, i.e. it is possible to design membranes having desired release characteristics e.g. a quick or a slow release of nicotine dependent on the purpose of the composition.
- desired release characteristics e.g. a quick or a slow release of nicotine dependent on the purpose of the composition.
- the specific features of a membrane or a membrane material can be used to design a controlled and well-defined release profile for the release of nicotine from a composition according to the invention.
- Membranes made from regenerated cellulose acetate dialysis tubing with varying thickness and molecular weight cut-off were tested for their selectivity in transporting nicotine across the membrane, while unwanted and potentially harmful substances are retained in the tobacco.
- the Impurity Index - lPl - was introduced as a measure for the selective release of nicotine.
- the IPI is calculated from the UV-spectra recorded from 200 nm to 900 nm, and is defined as the ratio of the sum of peak heights other than that of nicotine (i.e. thus including unwanted and harmful substances) to the peak height of nicotine. All measurements are performed in the receiver chamber, i.e. after permeation through the membrane in question. The IPI is measured 3, 30 and 90 min after start of the experiment, cf. above. In those cases where any additionally substances are added to the tobacco composition such as, e.g., sweeteners, flavors, detergents, buffers, etc. the peak heights of these are normally not included when calculating the sum of peak height as described above.
- IPI Impurity index
- the decrease in lPl is not merely a result of a decrease in the overall release rate. Accordingly, the release profiles relating to nicotine and employing cellulose membranes with a molecular weight cut-off of 13,000 are only a few percent lower than the release profile for the reference filter paper. Thus, employment of such membranes enables a release, which permits release of wanted substances (i.e. nicotine) while retaining unwanted substances.
- Example 2 shows that no significant loss in membrane selectivity is observed as the membrane thickness is being decreased. Therefore, further studies to investigate the relationship between membrane thickness, molecular weight cut-off of the membrane and amount of nicotine transferred over the membrane were performed by analyzing selected data from Example 1.
- the maximum slope for each release profile has been deduced.
- the maximum slope i.e. percentage nicotine release per time unit, dR/dt represents the maximum flux of nicotine through the membranes (see Table 4).
- Figure 3 shows a plot of the maximum flux as a function of membrane thickness for the cellulose membrane with a molecular weight cut-off of 13,000.
- the Figure shows that the flux of nicotine through a membrane is approaching the flux through a reference filter paper, which practically has no barrier to the nicotine diffusion, at a membrane thickness of about 10 ⁇ m.
- a hydrophilic membrane with a molecular cut off about 13,000 does not seem to give rise to any boundary layer/membrane effects or any major diffusion limitations for nicotine.
- a thickness of approx.10 ⁇ m will give a release profile equal to the original commercially available non-woven moist snuff pouches.
- the sensation of taking up nicotine into the blood stream from the oral cavity was scored using a scale rating from zero to five, with zero indicating no feeling and 5 indicating a very strong feeling of uptake, leading to dizziness and nausea.
- the results show that the effect of nicotine uptake from the novel snuff composition is slightly delayed compared to the sensation of nicotine uptake from the commercially available bag snuff.
- the volunteers feel an effect rated 5 after 8 to 10 minutes.
- the volunteers feel the maximum effect between 12 to 16 minutes.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacture Of Tobacco Products (AREA)
- Cosmetics (AREA)
Abstract
Description
- The present invention relates to a novel composition for the use as snuff in the oral cavity, the composition comprising tobacco and/or tobacco in combination with a tobacco substitute encapsulated in a membrane material comprising one or more membranes at least one of which being water permeable and water-insoluble. A novel composition enables a selective release of e.g. nicotine while it at the same time reduces the release of substances, which normally lead to unwanted side effects. The novel compositions may be used as a healthier alternative to snuff and other tobacco products such as, e.g., cigarettes, cigars and pipe.
- The invention also relates to methods for giving up smoking, reducing nicotine craving, reducing side effects normally related to smoking and snuffing of tobacco as well to a method for the preparation of a composition according to the invention.
- The use of tobacco is deeply rooted in a large part of the world population. In the Scandinavian countries and in particular Sweden the use of moist snuff (snus) is very common as an alternative to smoking. Snuff is fermented and milled/grinded tobacco with a relatively large water content (40 - 60 % w/w), normally to be used under the front upper lip of a human being.
- Tobacco itself varies somewhat in nicotine content due to its natural origin. To adjust the nicotine release in moist snuff, various buffer systems may be added, e.g. carbonates. The moist snuff is either packed loosely, as bulk in a box or as single doses in small non-woven bags. A number of the filled and sealed bags are then packed in a box.
- The moist snuff as a single dose has become popular due to the ease of use compared to the bulk product. The popularity of moist snuff is most probably due to its pharmacological nicotine absorption profile. The dose of nicotine and speed of absorption is approximately 10 ng per ml over 10 minutes. Plasma nicotine concentrations rapidly increase within the first few minutes of the use of snuff and reach levels comparable to those obtained from smoking cigarettes within 30 min of use. Measurements of plasma nicotine concentrations after a single day of moist snuff consumption also yielded levels similar to cigarette use.
- The kinetics is slightly slower compared to the kinetics when smoking tobacco, such as e.g. cigarettes and cigars; however, the overall amount of nicotine absorbed is higher when snuff is employed.
- Like the daily use of cigarettes, cigar, pipe and other smoke products, a daily use of snuff burdens the users body with a number of harmful compounds endogenous to tobacco.
- The disadvantage of snuff is the vast number of compounds, more or less harmful to the body, e.g. different tobacco-specific nitrosamines, which are compounds known to cause different diseases such as, e.g., gastro-intestinal disorders and cancer.
- Various tobacco products and/or devices for tobacco products wherein the user achieves the desired effect from nicotine, but at the same time avoids the harmful substances released from the tobacco are already known from the literature.
- In
US 4,848,376 an inhalation device is presented where tobacco is used more or less as in a cigarette and the nicotine is liberated due to elevated temperatures, though below the combustion temperature of tobacco. -
US 4,141,369 describes a method of inhaling the nicotine from tobacco without combustion of the tobacco. - Another way of avoiding the harmful substances contained in tobacco is to substitute tobacco with nicotine.
- In
US 4,655,231 an artificial dry snuff containing nicotine is suggested. The snuff, composed of pure nicotine salts and excipients e.g. powdered organic sugars, is intended for the administration to the nasal membranes. This is a medicinal nasal composition not based on natural tobacco. - Various devices have also be constructed in order to deliver nicotine from a tobacco composition placed in the oral cavity:
-
US 5,346,734 describes a perforated latex oral pouch for loose, moist snuff, the pouch serving as a barrier to avoid direct physical contact between the tobacco product and the gum. The pouch has to be filled by the user, cut to fit the mouth cavity of the user and is re-usable. -
US 6,162,516 describes a shield, which also has to be filled with snuff by the user, the shield acting as a barrier to reduce tobacco contact with the sensitive inner cheek lining and gum surfaces while using snuff. - Both
US 5,346,734 andUS 6,162,516 do provide the user with a protective device to avoid a direct contact of the tobacco fibers in the snuff with the oral tissues, but no means have been taken in order to avoid or reduce the release of potentially harmful and unwanted substances. Thus, potentially harmful and unwanted substances are still released from the tobacco into the oral cavity. - None of the above documents has solved the problems concerning eliminating or delaying the release in the oral cavity of unwanted and harmful substances when using a tobacco containing product as a snuff. Thus, there is still a need for the development of tobacco containing products, which do not deliver unwanted and harmful substances to the body after application.
- Accordingly, the present invention provides a composition wherein the release of nicotine from snuff can be designed freely, even though the release of unwanted and harmful substances from the tobacco is dramatically reduced.
- Thus, the present invention provides a composition for use in the oral cavity comprising tobacco and/or tobacco in combination with a tobacco substitute encapsulated in a membrane material comprising one or more membranes at least one of which being water permeable and water-insoluble.
- The gist of the invention is the employment of a membrane material which makes it possible to deliver nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof in a predetermined manner and - at the same time - has the properties of withholding the substances which are unwanted to such a degree that the side-effects normally observed in connection with the use of snuff in the oral cavity are dramatically reduced.
- The tobacco used in the novel snuff composition according to the invention may be natural tobacco leaves in order to preserve the authentic taste and feeling of tobacco. The tobacco plant belongs to the family Solanaceae and the genus Nicotiana. More than 60 tobacco species exists, the most commonly used in smoking or snuffing tobacco products being Nicotiana tabacum and Nicotiana rustica. To manufacture moist snuff, the tobacco, which typically has a content of from about 1% to 8% nicotine, is dried, milled and mixed with a fermentative solution. The mixture is then fermented, typically for 5 days to 4 weeks at elevated temperature. After this the tobacco mass is mixed with a suitable buffer, such as e.g. carbonate, so a pH of about 6 to 8 for the moist snuff mixture is obtained, to enable and enhance the release of nicotine or a derivative thereof from the tobacco. The water content in the final product may lie in the range from about 10 % to about 60 %.
- To the moist snuff additional compounds may be added, such as e.g. sweeteners, aroma substances and other taste additives, detergents and preservative, release modifying agents, and other liquids such as oil, organic solvents and herbal extracts.
- In another embodiment of the invention the natural fermented tobacco may be partly substituted with a tobacco substitute, such as, e.g., nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof selected from the group consisting of nor-nicotine, lobeline, methylanabasine, anabasine, nicotine hydrochloride, nicotine dihydrochloride, nicotine sulphate, nicotine monotartrate, nicotine bitartrate, nicotine salicylate or nicotine zinc chloride monohydrate. To maintain the same feeling of having the moist snuff product in the oral cavity, some additional filler may be added, such as, e.g., non-digestible fibers.
- Whether natural tobacco and/or tobacco in combination with a tobacco substitute are used for the novel snuff composition, the tobacco and/or tobacco substitute may preferably have a content of nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof, from about 0% w/w to about 30% w/w such as, e.g., from about 0.5% w/w to about 25% w/w, from about 0.1% w/w to about 20% w/w, from about 0.1% w/w to about 15% w/w, from about 0.1% w/w to about 10% w/w, from about 0.1% w/w to about 9% w/w or from about 0.1% w/w to about 8% w/w.
- According to the invention, the tobacco and/or tobacco substitute is enclosed in a membrane material. The membrane material may comprise one or more membranes. In the present context the term "membrane" describes a thin polymeric film having natural pores and acting as a selective permeability barrier. The term does not include papermade material or polymeric materials in which not-naturally occurring openings have been made.
- At least one of the membranes may be water-insoluble to prevent spreading of the snuff in the oral cavity, and to maintain the beneficial properties of the selective membrane material during use, with respect to the withholding of unwanted substances.
- At least one of the membranes may be water permeable in order to allow water to diffuse into the encapsulated tobacco and/or tobacco substitute and to allow e.g. nicotine to diffuse through the polymeric membrane material and thus becoming available for absorption.
- The membranes may have a predominantly hydrophilic or hydrophobic nature. The hydrophilic or hydrophobic nature of the membrane has an effect on the release of substances such as, e.g., nicotine through the membrane, since the flow of substances through the membrane is dependent on the ability of the membrane to hydrate, e.g. create hydro-channels through the membrane. These hydro-channels are a prerequisite for molecular transport when dry polymeric membranes are used. In general, the flow of hydrophilic substances through a hydrophobic membrane is slower compared to a hydrophilic membrane. This is probably due to less swelling of the hydrophobic membrane pores, i.e. in the hydrophobic membranes nicotine diffusion occurs through well-organized polymeric material and hydrophobic organized water.
- One or more of the membranes used for making the composition may be a synthetic or semi-synthetic membrane. Below is given some examples of natural, synthetic and semi-synthetic hydrophilic and hydrophobic membranes, which may be used in a novel snuff composition according to the invention.
- Examples of membranes are membranes made of cellulose acetate and derivates thereof, carboxymethyl cellulose membranes, polycellulose ester membranes, other cellulose derivatives such as, e.g., ethylcellulose, propylcellulose, polyethylene membranes, polypropylene membranes, polystyrene membranes, polyvinyl chloride membranes, polyvinyl acetate membranes, membranes made of polymers of methacrylates and acrylates, natural rubber membranes, polycarbonate membranes, polyethylene terephthalate membranes, polyester membranes, polyamide membranes and nylon membranes.
- At least the outer membrane in the membrane material enclosing the tobacco and/or tobacco substitute may be made from a biocompatible and physiologically acceptable polymeric material, since the novel snuff composition has to be placed close to or in contact with the mucous membrane in the oral cavity during use.
- Furthermore, at least one of the membranes in a membrane material may be surface treated with e.g. polycarbophils to obtain a bioadhesiveness of the novel snuff composition in the oral cavity.
- The molecular weight cut off of the membrane material used in the novel snuff composition may be varied to obtain a desired release of nicotine and other substances through the membrane material. The molecular weight cut-off of a membrane is defined as the molecular weight of the smallest molecule of which 90 % will be prevented from permeating the membrane. In addition to molecular weight, the exact permeability of a molecule is dependent on the shape, the degree of hydration and the charge of the molecule.
- At least one of the membranes comprising the membrane material may have a molecular weight cut-off from about 500 to about 40,000 such as, e.g., from about 500 to about 5,000, from about 800 to about 4,000, from about 1,000 to about 3,500; or from about 2,000 to about 40,000, from about 3,000 to about 30,000, from about 5,000 to about 25,000, from about 7,500 to about 20,000 or from about 10,000 to about 20,000.
- The release of nicotine and/or other substances through the membrane material is also dependent on the thickness of the membrane materiel. The diffusion process of molecules through the membrane is decreased when the membrane thickness is increased and vice versa. Thus, the thickness of the membrane material may be varied in respect of obtaining a desired release of nicotine and other substances through the membrane material.
- The lower limit for the membrane material thickness is determined by what is possible from a practical point of view, and the upper value is restricted by what will allow a comfortable fit of the novel snuff composition in the oral cavity of the user.
- Accordingly, at least one of the membranes comprising the membrane material may have a thickness of from 2 to about 200 µm such as, e.g., from about 5 to about 100 µm, from about 7.5 to about 50 µm, from about 7.5 to about 40 µm, from about 7.5 to about 35 µm, from about 7.5 to about 30 µm or from about 7.5 to about 25 µm.
- To obtain an effect from the novel snuff composition, nicotine or a nicotine derivative, analog, salt, solvate or a mixture thereof, selected from the group consisting of nor-nicotine, lobeline, methylanabasine, anabasine, nicotine hydrochloride, nicotine dihydrochloride, nicotine sulphate, nicotine monotartrate, nicotine bitartrate, nicotine salicylate or nicotine zinc chloride monohydrate, has to be released from the composition.
- The release profile may be designed with respect to the rate and amount of nicotine and unwanted substances released by the membrane.
- The release of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from a novel snuff composition may be designed to be released in a sufficient amount and/or a sufficient rate to enable a desired effect and on the other hand be designed to retain substances, which normally give rise to side-effects, such as, e.g., nitrosamines, and/or to release such substances in a substantially low amount and/or at a substantially slow rate.
- As a measure of the selective release of nicotine or a derivative, analog, salt, solvate or a mixture thereof, the Impurity Index- IPI - is introduced.
- The IPI is calculated from the UV-spectra recorded from 200 nm to 900 nm as described in Example 2, and is defined as the ratio of the sum of peak heights other than that of nicotine (i.e. thus including unwanted and harmful substances) to the peak height of nicotine. In other words, a low IPI reflects that a large amount of nicotine is released through the membrane compared to the amount of unwanted substances.
- In a preferred embodiment of the invention the impurity index IPI is at the most 3.0 such as, e.g. at the most 2.75, at the most 2.5, at the most 2.0, at the most 1.75, at the most 1.5, at the most 1.5 or at the most 1.4 when measured after 90 min.
- In one embodiment of the invention the release profile of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from the invention could e.g., be fast and equivalent to the release of nicotine from the commercially available moist snuff, while maintaining a low IPI value, i.e. limiting the release of unwanted substances.
- Moreover, a composition according to the invention can be designed to release nicotine and/or a derivative, analog, salt, solvate or mixture thereof in a controlled manner such as, e.g., fast (faster than from the reference product employed in the examples herein), relatively fast (i.e. similar or almost similar to the reference product employed in the examples herein), delayed (i.e. with a lag time in which period no nicotine is released followed by a release of nicotine), prolonged or sustained (i.e. a relatively slower release than the reference product to avoid any peak concentration and to obtain a relatively constant plasma concentration of nicotine after application).
- In another embodiment of the invention the release of nicotine or a derivative, analog, salt, solvate or a mixture thereof, may be delayed compared to the commercially available moist snuff, to mimic the effect of nicotine replacement products such as, e.g., patches.
- The release of nicotine or a derivative, analog, salt, solvate or a mixture thereof, may be determined by the release test described in Example 1, but other suitable methods for determining the release of nicotine may also be used, i.e. the embodiments of the invention described below referrer to Example 1 without limiting the relevant release tests to the one described in Example 1.
- The tobacco and/or tobacco in combination with a tobacco substitute composition may be designed so that at least about 50% w/w of the total content of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof is released within at the most 60 min when subject to the release test described in Example 1 below.
- In a further embodiment of the invention the tobacco and/or tobacco substitute composition may be designed so that at the most 25% w/w of the total content of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof is released within at the most 60 min when subject to the release test described in Example 1 below.
- In yet another embodiment the tobacco and/or tobacco substitute composition may be designed so that at least about 50% w/w of the total content of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof is released within at the most 120 min when subject to the release test described in Example 1 below.
- Below follows release profiles for compositions according to the invention. The release profiles are described as %w/w released of total nicotine content as a function of time, measured at 0, 3, 30, 90 and 180 minutes. However, the release profiles according to the invention also includes profiles described by only one or any combination of the values below, i.e. a release profile according to the invention could be defined by e.g. the %w/w release of nicotine at 3 minutes and 90 min, or at 3 and 90 and 180 minutes, or at 90 and 180 minutes or any possible combination of the values shown below.
- A composition according to the invention is suitable designed to release nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from the tobacco or tobacco in combination with the tobacco substitute with the following characteristics:
time (min) % w/w released of total nicotine content 0 from about 0 to about 20 such as, e.g., from about 0 to about 15 or from about 0 to about 10, 3 from about 0 to about 40 such as, e.g., from about 0 to about 35, from about 0 to about 30, from about 0 to about 25, from about 0 to about 20, 30 from about 2 to about 100, such as, e.g., from about 2 to about 90, from about 2 to about 80, from about 2 to about 70, from about 2 to about 65, from about 2 to about 60, from about 5 to about 60, from about 5 to about 55, from about 7.5 to about 55 or from about 10 to about 50, op til 100 90 from about 10 to about 100 such as, e.g., from about 10 to about 95, from about 15 to about 90, from about 20 to about 90, from about 25 to about 85, from about 30 to about 80, from about 35 to about 80 or from about 40 to about 80, 180 from about 40 to about 100 such as, e.g. from about 45 to about 100, from about 50 to about 100, from about 55 to about 100, from about 60 to about 100, from about 65 to about 100 or from about 70 to about 100, - More specifically, a composition according to the invention releases nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from the tobacco or the tobacco in combination with a tobacco substitute with the following release profile characteristics:
time (min) % w/w released of total nicotine content 0 from about 0 to about 15 3 from about 1 to about 25 30 from about 7.5 to about 55 90 from about 35 to about 80 180 from about 65 to about 100 - In a further embodiment, a composition according to the invention releases, nicotine and/or derivative, analog, salt or solvate thereof from the tobacco or the tobacco in combination with a tobacco substitute with the following release profile characteristics:
time (min) % w/w released of total nicotine content 0 from about 0 to about 10 3 from about 1 to about 20 30 from about 10 to about 50 90 from about 40 to about 90 180 from about 70 to about 100 - In a still further embodiment, a composition according to the invention releases nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from the tobacco or the tobacco in combination with a tobacco substitute with the following release profile characteristics:
time (min) % w/w released of total nicotine content 0 from about 0 to about 10 3 from about 1 to about 20 30 from about 30 to about 50 90 from about 65 to about 90 - As described above, membrane material properties such as hydrophobicity, hydrophilicity, molecular weight cut-off and membrane thickness may be used in designing a desired release profile for nicotine or a derivative, analog, salt, solvate or mixture thereof.
- In the following are given some examples of how membrane materials can be designed. The examples are for illustrative purposes and are not intended to limit the invention in any way.
- A multi-layer membrane is e.g. designed to contain one membrane material being hydrophilic and a second membrane material being lipophilic. Both membrane components are chosen in such a manner that the membrane material has a molecular cut off large enough for the relatively small nicotine molecule to pass through with ease.
- The amphiphilic nature of nicotine enables it to pass both hydrophilic and hydrophobic materials while a majority of both hydrophilic and lipophilic unwanted and harmful substances are excluded from permeation through the membrane material. Many other combinations of different types of membranes are of course possible and based on the disclosure herein a skilled person will know how to chose different membranes in order to obtain a suitable release.
- Another example of a composition according to the invention is a composition wherein the membrane material is a bi-layer membrane with one membrane being preferentially hydrophilic and one membrane being predominantly hydrophobic. Both membranes possess high permeability to nicotine while maintaining low aqueous pore diffusion. The release profile of nicotine could either be identical to the release profile of original snuff or it could be designed to have a prolonged or sustained release. The unwanted and harmful substances from the tobacco should substantially be maintained inside the membrane.
- A composition according to the invention may attain all possible sizes and shapes, such as, e.g. round, circular, oblong, elliptical, square, rectangular or trapezoidal. The shape and/or size chosen may be such as to allow a comfortable fit in the oral cavity.
- The location in the oral cavity of a composition according to the invention may be centered or to the sides under the upper front lip, centered or to the sides under the lower front lip, under the tongue or in the cheeks.
- In other aspects, the invention also relates to use of a composition according to the invention as a smoke substitute and it can be used by persons who suffer from nicotine craving or who want to give up or reduce smoking. In such cases, the content of tobacco and/or a tobacco substitute is adjusted to the individual purposes and it is possible to design a kit comprising compositions according to the invention with different concentrations of tobacco and/or a tobacco substitute. Such compositions in a kit could e.g. contain compositions with a decreasing content of tobacco or nicotine.
- In a still further aspect of the invention it relates to a method for preparing a composition according to the invention.
- The details and description relating to the composition aspects apply mutatis mutandi to the other aspects of the invention.
-
- Figure 1 shows the release profile from moist tobacco using side-by-side diffusion cells equipped with specific membranes having different physical properties.
- Figure 2 shows the impurity index (IPI) for various hydrophilic membranes with different thickness and molecular weight cut-offs. The reference is filter paper.
- Figure 3 shows the maximum flux of nicotine as a function of membranes thickness for a hydrophilic membrane with a molecular weight cut-off of 13,000. The reference flux illustrates the flux through filter paper.
- The following examples are intended to illustrate the invention without limiting it thereto.
- Membranes made of regenerated cellulose acetate dialysis tubing with varying MW cut-off together with vinyl and polyethylene membranes with various thicknesses were tested with respect to the diffusion profiles over the membranes of nicotine released from tobacco.
- In a side-by-side diffusion chamber separated by a membrane, 1 g of snuff tobacco (SVENSKT SNUS, GOTHIATEK, General) was placed in an aqueous PBS (phosphate buffered saline according to Ph. Eur.) with a pH of 6.6 on the donor side of the membrane in the diffusion chamber. In the receiver chamber PBS with a pH of 6.6 was placed. The cells of the diffusion chamber were kept at a temperature of 37°C ± 0.5°C by attachment to a water bath. The temperature control was made in order to simulate the environment of the oral cavity.
- Diffusion profiles were constructed by sampling from the receiver chamber at 0, 3, 30, 60, 90, 120, (110 min for the polyethylene membrane) and 180 min after the start of the diffusion experiment. The concentration of nicotine in the receiver chamber was measured by HPLC, using a C-18, 5µ, 4.5 mm x 15 cm column, employing a mobile phase consisting of 70 % v/v 0.1 M phosphate buffer (pH 4.5), 30 % acetonitrile, and 2.3 g sodium dodecyl sulphate/liter at a flow rate of 1 ml /min and a temperature of 40°C. The sample volume was 10 µl and detection was carried out using a UV-detector running at 260 nm.
- The membranes used were regenerated cellulose acetate dialysis tubing with varying MW cut-off and vinyl and polyethylene membranes with varying thickness.
- As a reference a piece of filter paper with a average pore size of 8.8 µm, mimicking the commercially used non-woven bag for snuff, was used.
- Table I shows a comparison of the release profile of nicotine for a commercial non-woven snuff-bag, and a piece of filter paper used as reference in the experiments. The measurements were performed as described above, and the results are the mean of 2 single runs.
Table I. Comparison of the nicotine release profile for a commercial non-woven filter and a reference paper filter Filter type Nicotine released (mg/ml) 15 sec. 30 min. 60 min. 90 min. Reference paper filter 11.5 64.4 92.0 202.4 Commercial non-woven filter 9.4 65.8 90.1 205.5 - The results from Table I show that the reference filter paper exerts no barrier function to the transport of nicotine.
- Hydrophobic membranes, e.g. vinyl and polyethylene membranes, show a slower nicotine release profile compared to hydrophilic membranes (see Figure 1). The slower profile is probably due to less swelling of the hydrophobic membrane pores, i.e. in the hydrophobic membranes nicotine diffusion occurs through well-organized polymeric material and hydrophobic organized water rather than through aqueous pores.
- In Table 2 below are given the results from the above-mentioned experiment.
- Figure 1 shows that the release of nicotine over a hydrophilic membrane made of regenerated cellulose acetate dialysis tubing is high and close to the nicotine release over the reference filter paper. Figure 1 also shows that the physical properties, i.e. the molecular weight cut-off and thickness of the hydrophilic membrane, affect the permeability of nicotine as stated below.
- A membrane with a relatively small molecular weight cut-off, e.g. a molecular weight cut-off of 3,500, tends to have a sigmoid release profile for nicotine. In other words, a considerable lag time is expected before the nicotine starts to permeate the membrane, even though the size of a nicotine molecule is significantly smaller than the molecular weight cut-off of 3,500.
- However, a membrane with a higher molecular weight cut-off, e.g. a molecular weight cut-off of 13,000, seems to have a release profile for nicotine that is very close to the release profile for nicotine of the reference filter paper.
- This difference may be due to a much lower aqueous mobility of nicotine in the membrane with a molecular weight cut-off of 3,500, compared to the membrane with a molecular weight cut-off of 13,000.
- Figure 1 also shows that when the thickness of a membrane increases, then the flux of nicotine through the membrane decreases.
- Example 1 shows that it is possible to design a polymeric membrane which gives rise to a release profile of nicotine from moist tobacco through the membrane very similar to the release profile through a commercial non-woven snuff-bag, i.e. with respect to the shape of the profile and the individual release data (time, percentage released). Especially, it seems that a hydrophilic membrane material is suitable. Furthermore, the release profile is dependent of the molecular weight cut-off of the membrane, the thickness of the membrane and of the membrane material itself.
- Example 1 also shows that some hydrophobic membranes, e.g. vinyl and polyethylene membranes, have a slower nicotine release profile compared to the hydrophilic membranes.
- All these observations make it possible to design membranes, which enable a specific release of nicotine, i.e. it is possible to design membranes having desired release characteristics e.g. a quick or a slow release of nicotine dependent on the purpose of the composition. In other words, the specific features of a membrane or a membrane material can be used to design a controlled and well-defined release profile for the release of nicotine from a composition according to the invention.
Table 2: Release of nicotine from membranes of various kinds, thicknesses and pore sizes Membrane Release of nicotine (%) 0 min 3 min 30 min 90 min 120 min 180 min Reference filter (original) 4.7 18.7 46.5 80.8 88.8 100 23 µm cellulose membrane 13,000 MW cut-off 2.4 4.1 36.6 73.2 83.7 100 46 µm cellulose membrane 13,000 MW cut-off 1.6 2.4 33.3 69.1 79.2 100 93 µm cellulose membrane 13,000 MW cut-off 0 0 17.2 43.9 49.0 69.7 25 µm cellulose membrane 3,500 MW cut-off 0.9 2.7 11.6 67.0 75.9 100 50 µm cellulose membrane 3,500 MW cut-off 0.9 1.7 4.3 49.9 56.8 80.0 20 µm Polyetylene 0 0 3.0 -- 22* -- * Measured after 110 min - Membranes made from regenerated cellulose acetate dialysis tubing with varying thickness and molecular weight cut-off were tested for their selectivity in transporting nicotine across the membrane, while unwanted and potentially harmful substances are retained in the tobacco.
- To examine the selectivity of the membranes, an experimental set-up as described in Example I was used.
- As membranes were used regenerated cellulose acetate with molecular weight cut-off of 3,500 and a thickness of 25.2 µm or a molecular weight cut-off of 13,000 and a thickness of 23.2 µm or 46.4 µm. Samples were withdrawn at 3, 30 and 90 minutes after the start of the experiment and an UV spectrum from 200 nm to 900 nm was recorded for each sample.
- As previous described, the Impurity Index - lPl - was introduced as a measure for the selective release of nicotine. The IPI is calculated from the UV-spectra recorded from 200 nm to 900 nm, and is defined as the ratio of the sum of peak heights other than that of nicotine (i.e. thus including unwanted and harmful substances) to the peak height of nicotine. All measurements are performed in the receiver chamber, i.e. after permeation through the membrane in question. The IPI is measured 3, 30 and 90 min after start of the experiment, cf. above. In those cases where any additionally substances are added to the tobacco composition such as, e.g., sweeteners, flavors, detergents, buffers, etc. the peak heights of these are normally not included when calculating the sum of peak height as described above.
- As mentioned before, a low IPI reflects that a large amount of nicotine is released through the membrane compared to the amount of unwanted substances. Table 3 shows IPI values calculated for the reference filter paper and for hydrophilic membranes with different molecular weight cut-off and different thickness.
Table 3: Impurity index (IPI) calculated for the reference filter paper membrane and hydrophilic regenerated cellulose acetate membranes with different physical properties Time Impurity index (IPI) (min) Membrane 1Membrane 2Membrane 3Reference Thick: 25.2 µm Thick: 23.2 µm Thick 46.4 µm MWCO 3,500 MWCO 13,000 MWCO 13,000 3 0.9 0.75 1.05 1.64 30 1.17 1.24 1.17 2.91 90 1.26 1.35 1.25 3.35 IPI = Σ Peak height other substances/ Σ Peak height nicotine
MWCO = molecular weight cut-off - The results in Table 3 show that the amount of unwanted substances can be decreased almost three times when a cellulose membrane with a thickness and a molecular weight cut-off in the range described in Table 3 is used compared to the reference filter paper.
- As shown in Figure 1, the decrease in lPl is not merely a result of a decrease in the overall release rate. Accordingly, the release profiles relating to nicotine and employing cellulose membranes with a molecular weight cut-off of 13,000 are only a few percent lower than the release profile for the reference filter paper. Thus, employment of such membranes enables a release, which permits release of wanted substances (i.e. nicotine) while retaining unwanted substances.
- The results from Table 3 and Fig. 1 indicate that the release rate of unwanted substances increases with decreasing membrane thickness. However, it is important to note that such an increase seems to correspond to the increase in the release rate of nicotine, i.e., a decrease in membrane thickness will not lead to a more pronounced release of unwanted substances. In other words, the IPI value is not increasing when the thickness of the membrane with a molecular weight cut-off of 13,000 is decreased from 46.4 µm to 23.2 µm.
- Example 2 shows that no significant loss in membrane selectivity is observed as the membrane thickness is being decreased. Therefore, further studies to investigate the relationship between membrane thickness, molecular weight cut-off of the membrane and amount of nicotine transferred over the membrane were performed by analyzing selected data from Example 1.
-
- Figure 3 shows a plot of the maximum flux as a function of membrane thickness for the cellulose membrane with a molecular weight cut-off of 13,000. The Figure shows that the flux of nicotine through a membrane is approaching the flux through a reference filter paper, which practically has no barrier to the nicotine diffusion, at a membrane thickness of about 10 µm.
- A hydrophilic membrane with a molecular cut off about 13,000 does not seem to give rise to any boundary layer/membrane effects or any major diffusion limitations for nicotine. A thickness of approx.10 µm will give a release profile equal to the original commercially available non-woven moist snuff pouches.
- The sensation of nicotine uptake in humans when using commercially available bag-snuff compared to a novel snuff composition according to the invention was studied.
- In the study, the uptake of nicotine from 1 g of snuff (SVENSKT SNUS, GOTHIATEK, General) in original non-woven pouches was compared to the uptake of nicotine from 1 g of snuff contained in a regenerated cellulose membrane with a molecular weight cut-off of 13,000 and a thickness of 23.2 µm.
- The study was performed with human volunteers who were not snuff users.
- Each individual placed a portion of snuff under the upper lip, and they scored their observations concerning the sensation of taking up nicotine into the blood stream within certain time intervals.
- The sensation of taking up nicotine into the blood stream from the oral cavity was scored using a scale rating from zero to five, with zero indicating no feeling and 5 indicating a very strong feeling of uptake, leading to dizziness and nausea.
-
- It is evident from the results shown in Table 5, that the novel snuff composition gives rise to a nicotine effect in the volunteers. Four minutes after the commercially available bag snuff or the novel snuff composition was placed in the oral cavity, two of the volunteers felt a nicotine effect, which they gave a scoring of one. One of the volunteers felt an one-degree higher effect from the commercially available bag snuff compared to the novel snuff composition
- The results also show that the effect of nicotine uptake from the novel snuff composition is slightly delayed compared to the sensation of nicotine uptake from the commercially available bag snuff. When using the commercially available bag snuff, the volunteers feel an effect rated 5 after 8 to 10 minutes. When using the novel snuff composition the volunteers feel the maximum effect between 12 to 16 minutes.
Claims (39)
- A composition for use in the oral cavity comprising a material selected from the group consisting of tobacco and tobacco in combination with a tobacco substitute, the material being encapsulated in a membrane material comprising one or more membranes at least one of which being water permeable and water-insoluble, and wherein the impurity index of the composition - when determined as described herein - is at the most 3.0 such as, e.g., at the most 2.75, at the most 2.5, at the most 2.0, at the most 1.75, at the most 1.5, at the most 1.5 or at the most 1.4 when measured after 90 min.
- A composition according to claim 1 for use as snuff.
- A composition according to claim 1 or 2, wherein the composition is not in the form of a chewing gum.
- A composition according to any of the preceding claims, wherein at least one membrane is a synthetic or semi-synthetic membrane.
- A composition according to any of the preceding claims, wherein at least one membrane is made from natural rubber.
- A composition according to any of the preceding claims, wherein at least one membrane is a biocompatible membrane.
- A composition according to any of the preceding claims, wherein the membrane is of a polymeric material such as one selected from the group consisting of cellulose acetate and derivates thereof, carboxymethyl cellulose, polycellulose esters, other cellulose derivatives such as, e.g., ethylcellulose, propylcellulose, polyethylene, polypropylene, polystyrene, polyvinyl chloride, polyvinyl acetate, polymers of methacrylates and acrylates, natural rubber, polycarbonates, polyethylene terephthalate, polyesters, polyamides and nylon.
- A composition according to any of the preceding claims, wherein at least one of the membranes has predominantly hydrophilic character.
- A composition according to any of the preceding claims, wherein at least one of the membranes has predominantly hydrophobic character.
- A composition according to any of the preceding claims, wherein nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof is released from the tobacco or the tobacco substitute.
- A composition according to claim 10, wherein the release is a controlled release.
- A composition according to claim 10 or 11, wherein the nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof is selected from the group consisting of nor-nicotine, lobeline, methylanabasine, anabasine, nicotine hydrochloride, nicotine dihydrochloride, nicotine sulphate, nicotine monotartrate, nicotine bitartrate, nicotine salicylate or nicotine zinc chloride monohydrate.
- A composition according to any of the preceding claims, which i) is designed to release nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof in a sufficient amount and/or at a sufficient rate to enable a desired effect and ii) is designed to retain substances, which normally give rise to side-effects, and/or to release such substances in a substantially low amount and/or at a substantially slow rate.
- A composition according to any of the preceding claims, Wherein at least one of the membranes comprising the membrane material has a molecular weight cut-off of from about 500 to about 40,000 such as, e.g., from about 500 to about 5,000, from about 800 to about 4,000, from about 1,000 to about 3,500, or from about 2,000 to about 40,000, from about 3,000 to about 30,000, from about 5,000 to about 25.000, from about 7,500 to about 20,000 or from about 10,000 to about 20,000.
- A composition according to any of the preceding claims, wherein at least one of the membranes comprising the membrane material has a thickness of from about 2 to about 200 µm such as, e.g., from about 5 to about 100 µm, from about 7.5 to about 50 µm, from about 7.5 to about 40 µm, from about 7.5 to about 35 µm, from about 7.5 to about 30 µm or from about 7.5 to about 25 µm.
- A composition according to any of the preceding claims, wherein at least about 50% w/w of the total content of nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof is released within at the most 60 min when subject to the release test described herein.
- A composition according to any of claims 1-15, wherein at the most 25% w/w of the total content of nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof is released within at the most 60 min when subject to the release test described herein.
- A composition according to any of claims 1-15 or 17, wherein at least about 50% w/w of the total content of nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof Is released within at the most 120 min when subject to the release test described herein.
- A composition according to any of the preceding claims, wherein the release of nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof from the tobacco or the tobacco substitute has the following characteristics:
time (min) % w/w released of total nicotine content 0 from about 0 to about 20 such as, e.g., from about 0 to about 15 or from about 0 to about 10 3 from about 0.5 to about 40 such as e.g., from about 0.5 to about 35, from about 0.5 to about 30, from about 1 to about 25 or from about 1 to about 20 30 from about 2 to about 65 such as, e.g., from about 2 to about 60, from about 5 to about 60, from about 5 to about 55, from about 7.5 to about 55 or from about 10 to about 50 90 from about 10 to about 100 such as, e.g., from about 10 to about 95, from about 15 to about 90. from about 20 to about 90, from about 25 to about 85, from about 30 to about 80, from about 35 to about 80 or from about 40 to about 80 180 from about 40 to about 100 such as, e.g., from about 45 to about 100, from about 50 to about 100, from about 55 to about 100, from about 60 to about 100, from about 65 to about 100 or from about 70 to about 100 - A composition according to any of the preceding claims, wherein the release of nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof from the tobacco or the tobacco substitute has the following characteristics:
time (min) % w/w released of total nicotine content 0 from about 0 to about 15 3 from about 1 to about 25 30 from about 7.5 to about 55 90 from about 35 to about 80 180 from about 65 to about 100 - A composition according to any of the preceding claims, wherein the release of nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof from the tobacco or the tobacco substitute has the following characteristics:
time (min) % w/w released of total nicotine content 0 from about 0 to about 10 3 from about 1 to about 20 30 from about 10 to about 50 90 from about 40 to about 90 180 from about 70 to about 100 - A composition according to any of the preceding claims, wherein the release of nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof from the tobacco or the tobacco substitute has the following characteristics:
time (min) % w/w released of total nicotine content 0 from about 0 to about 10 3 from about 1 to about 20 30 from about 30 to about 50 90 from about 65 to about 90 - A composition according to any of the preceding claims wherein the tobacco is processed from the leafs of the plant family Solanaceae and the genus Nicotiana, such as, e.g., Nicotiana tabacum and Nicotiana rustica.
- A composition according to any of the preceding claims comprising nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof as claimed in claim 12 together with tobacco in the form of snuff tobacco and/or a suitable filler substance.
- A composition according to any of the preceding claims wherein the composition further comprises sweeteners, aromas, taste additives, detergents, pH adjusting substances, preservatives, buffers, release modifying agents and/or fillers.
- A composition according to any of the preceding claims wherein the composition further comprises chemical compounds that enables and enhances the release of nicotine from tobacco such as, e.g., pH regulating buffers, e.g. carbonates buffers oil, organic solvents and herbal extracts.
- A composition according to any of the preceding claims, wherein the tobacco or tobacco substitute contains nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof in an concentration of about from 0% w/w to about 30% w/w such as, e.g., from about 0.5% w/w to about 25% w/w, from about 0.1% w/w to about 20% w/w, from about 0.1% w/w to about 15% w/w, from about 0.1% w/w to about 10% w/w, from about 0.1% w/w to about 9% w/w or from about 0.1% w/w to about 8% w/w.
- A composition according to any of the preceding claims, wherein the membrane material is composed of at least two different kinds of membranes with respect to e.g. thickness, molecular weight cut-off, hydrophilic/hydrophobic nature and water permeability.
- A composition according to any of the preceding claims, wherein the composition has a size and/or shape, which is suitable for application under the upper lip of a human.
- A composition according to any of the preceding claims containing a mixture of tobacco and a tobacco substitute.
- A composition according to any of the preceding claims for use as a smoke substitute.
- A composition according to claim 30 or 31 for use in reducing nicotine craving and/or nicotine abstinence.
- A method for controlling the release of nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof from tobacco and/or tobacco substitute in the oral cavity, the method comprising encapsulating a material selected from the group consisting of tobacco and tobacco in combination with a tobacco substitute in a membrane material comprising one or more membranes at least one of which being water permeable and water-insoluble so that nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof is released in a sufficient amount and/or at a sufficient rate to i) enable a desired effect and ii) retain substances, which normally give rise to side-effects, and/or release such substances in a substantially low amount and/or at a substantially slow rate.
- A method for delivering nicotine and/or derivative, analog, salt or solvate thereof to a person in need thereof, the method comprising applying a composition according to any of claims 1-32 to the oral cavity.
- A method for giving up smoking, the method comprising applying a composition according to any of claims 1-32 to the oral cavity.
- Use of a composition according to any of claims 1-32 in the manufacture of a medicament for reducing nicotine craving, by applying said composition a composition according to any of claims 1-32 to the oral cavity.
- Use of a composition according to any of claims 1-32 in the manufacture of a medicament for reducing side effects related to smoking and/or snuffing tobacco, by applying said composition to the oral cavity.
- Use of a composition according to any of claims 1-32 as an alternative to and/or substitute for smoking tobacco.
- A method for the preparation of a composition according to any of claims 1-32, the method comprising encapsulating tobacco and/or a tobacco substitute in a membrane material comprising one or more membranes at least one of which being a water permeable and a water-insoluble membrane.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200101945 | 2001-12-21 | ||
DK200101945 | 2001-12-21 | ||
PCT/EP2002/014853 WO2003053175A2 (en) | 2001-12-21 | 2002-12-17 | Tobacco and/or tobacco substitute composition for use as a snuff in the oral cavity |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1458252A2 EP1458252A2 (en) | 2004-09-22 |
EP1458252B1 true EP1458252B1 (en) | 2008-01-23 |
Family
ID=8160931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02795287A Expired - Lifetime EP1458252B1 (en) | 2001-12-21 | 2002-12-17 | Tobacco and/or tobacco in combination with tobacco substitute composition for use as a snuff in the oral cavity |
Country Status (7)
Country | Link |
---|---|
US (1) | US20050061339A1 (en) |
EP (1) | EP1458252B1 (en) |
AT (1) | ATE384450T1 (en) |
AU (1) | AU2002360097A1 (en) |
DE (1) | DE60224832T2 (en) |
DK (1) | DK1458252T3 (en) |
WO (1) | WO2003053175A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008038556A1 (en) * | 2008-06-26 | 2009-12-31 | Eswegee Vliesstoff Gmbh | Nonwoven fabric for use as a moisture-permeable, microporous semi-luxury packaging material |
Families Citing this family (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4708795B2 (en) | 2002-12-20 | 2011-06-22 | ニコノヴァム エービー | Physically and chemically stable nicotine-containing particulate matter |
SE0302947D0 (en) | 2003-01-24 | 2003-11-07 | Magle Ab | A composition material for transmucosal delivery |
JP2008510486A (en) * | 2004-08-23 | 2008-04-10 | ユーエス スモークレス タバコ カンパニー | Tobacco with diversity |
SE0500006L (en) * | 2005-01-04 | 2006-07-05 | Peter Stigsson | Device for ingesting caffeine in an oral cavity |
CN101222861B (en) * | 2005-04-29 | 2010-09-08 | 菲利普莫里斯生产公司 | Tobacco pouch product |
US9044049B2 (en) | 2005-04-29 | 2015-06-02 | Philip Morris Usa Inc. | Tobacco pouch product |
US7861728B2 (en) * | 2006-02-10 | 2011-01-04 | R.J. Reynolds Tobacco Company | Smokeless tobacco composition having an outer and inner pouch |
WO2007037962A1 (en) | 2005-09-22 | 2007-04-05 | R.J. Reynolds Tobacco Company | Smokeless tobacco composition |
US20070062549A1 (en) * | 2005-09-22 | 2007-03-22 | Holton Darrell E Jr | Smokeless tobacco composition |
US8685478B2 (en) | 2005-11-21 | 2014-04-01 | Philip Morris Usa Inc. | Flavor pouch |
US7810507B2 (en) | 2006-02-10 | 2010-10-12 | R. J. Reynolds Tobacco Company | Smokeless tobacco composition |
CA2646942C (en) | 2006-03-16 | 2014-07-29 | Niconovum Ab | Improved snuff composition |
WO2008133563A1 (en) * | 2007-04-26 | 2008-11-06 | Swedish Match North Europe Ab | Moist non-tobacco snuff product |
SE529886C2 (en) | 2006-04-28 | 2007-12-18 | Swedish Match North Europe Ab | A new method for preparing a moisturizing snuff composition that does not contain tobacco |
WO2007144687A1 (en) * | 2006-06-12 | 2007-12-21 | Philip Morris Products S.A. | Non-tobacco pouch product |
US7766019B2 (en) * | 2006-07-21 | 2010-08-03 | Gp Technologies, Inc. | Porous plastic smoking cessation devices |
JP5941609B2 (en) * | 2006-08-01 | 2016-06-29 | アール・ジェイ・レノルズ・タバコ・カンパニーR.J.Reynolds Tobacco Company | Smokeless tobacco |
US20080029117A1 (en) * | 2006-08-01 | 2008-02-07 | John-Paul Mua | Smokeless Tobacco |
US20080029116A1 (en) * | 2006-08-01 | 2008-02-07 | John Howard Robinson | Smokeless tobacco |
US20080173317A1 (en) * | 2006-08-01 | 2008-07-24 | John Howard Robinson | Smokeless tobacco |
US9032971B2 (en) | 2006-11-15 | 2015-05-19 | Philip Morris Usa Inc. | Moist tobacco product and method of making |
US8616221B2 (en) | 2007-02-28 | 2013-12-31 | Philip Morris Usa Inc. | Oral pouch product with flavored wrapper |
US20080210249A1 (en) * | 2007-03-02 | 2008-09-04 | Luzenberg Robert S | Systems, devices and methods for delivering one or more additives to smokeless tobacco |
US20090032040A1 (en) * | 2007-03-30 | 2009-02-05 | Luzenberg Jr Robert S | Porous plastic smokeless tobacco substitutes |
US8356606B2 (en) | 2007-06-01 | 2013-01-22 | Philip Morris Usa Inc. | Production of micronized encapsulated tobacco particles for tobacco flavor delivery from an oral pouch |
US8162136B2 (en) * | 2007-06-04 | 2012-04-24 | British American Tobacco (Investments) Limited | Package for different tobacco products |
WO2009004488A2 (en) | 2007-06-08 | 2009-01-08 | Philip Morris Products S.A. | Capsule clusters for oral consumption |
US9888712B2 (en) * | 2007-06-08 | 2018-02-13 | Philip Morris Usa Inc. | Oral pouch products including a liner and tobacco beads |
US8029837B2 (en) * | 2007-06-08 | 2011-10-04 | Philip Morris Usa Inc. | Chewable pouch for flavored product delivery |
WO2009007854A2 (en) * | 2007-06-08 | 2009-01-15 | Philip Morris Products S.A. | Oral pouch product including soluble dietary fibers |
US8950408B2 (en) | 2007-07-16 | 2015-02-10 | Philip Morris Usa Inc. | Oral pouch product having soft edge |
WO2009010875A2 (en) * | 2007-07-16 | 2009-01-22 | Philip Morris Products S.A. | Oral delivery pouch product with coated seam |
WO2009010881A2 (en) | 2007-07-16 | 2009-01-22 | Philip Morris Products S.A. | Oral pouch products with immobilized flavorant particles |
WO2009010884A2 (en) | 2007-07-16 | 2009-01-22 | Philip Morris Products S.A. | Tobacco-free oral flavor delivery pouch product |
US8119173B2 (en) * | 2007-07-16 | 2012-02-21 | Philip Morris Usa Inc. | Method of flavor encapsulation through the use of a drum coater |
US7946295B2 (en) * | 2007-07-23 | 2011-05-24 | R. J. Reynolds Tobacco Company | Smokeless tobacco composition |
EP2179666B1 (en) | 2007-07-23 | 2012-08-29 | R.J.Reynolds Tobacco Company | Smokeless Tobacco Compositions And Methods For Treating Tobacco For Use Therein |
US8061362B2 (en) | 2007-07-23 | 2011-11-22 | R. J. Reynolds Tobacco Company | Smokeless tobacco composition |
US8312886B2 (en) * | 2007-08-09 | 2012-11-20 | Philip Morris Usa Inc. | Oral tobacco product having a hydrated membrane coating and a high surface area |
US9125434B2 (en) * | 2007-10-11 | 2015-09-08 | Philip Morris Products S.A. | Smokeless tobacco product, smokeless tobacco product in the form of a sheet, extrudable tobacco composition, method for manufacturing a smokeless tobacco product, method for delivering super bioavailable nicotine contained in tobacco to a user, and packaged smokeless tobacco product sheet |
CN107048483A (en) * | 2007-10-11 | 2017-08-18 | 菲利普莫里斯生产公司 | Smokeless tobacco product |
JP5193311B2 (en) * | 2007-12-21 | 2013-05-08 | スウィーディッシュ・マッチ・ノース・ヨーロップ・アーベー | Tobacco or non-tobacco products containing magnesium carbonate |
US8469037B2 (en) | 2008-02-08 | 2013-06-25 | Philip Morris Usa Inc. | Pre-portioned moist product and method of making |
US20100018540A1 (en) * | 2008-07-28 | 2010-01-28 | David James Doolittle | Smokeless tobacco products and processes |
US20100018541A1 (en) * | 2008-07-28 | 2010-01-28 | Anthony Richard Gerardi | Smokeless tobacco products and processes |
US20100018882A1 (en) * | 2008-07-28 | 2010-01-28 | St Charles Frank K | Smokeless tobacco products and processes |
US20100018539A1 (en) * | 2008-07-28 | 2010-01-28 | Paul Andrew Brinkley | Smokeless tobacco products and processes |
WO2010031552A1 (en) * | 2008-09-17 | 2010-03-25 | Niconovum Ab | Process for preparing snuff composition |
US20100116281A1 (en) * | 2008-11-07 | 2010-05-13 | Jerry Wayne Marshall | Tobacco products and processes |
US8377215B2 (en) | 2008-12-18 | 2013-02-19 | Philip Morris Usa Inc. | Moist botanical pouch processing |
CN102325472B (en) * | 2008-12-19 | 2015-07-29 | 美国无烟烟草有限责任公司 | The method of tobacco particle and production tobacco particle |
US9027567B2 (en) * | 2008-12-30 | 2015-05-12 | Philip Morris Usa Inc. | Oral pouch product with multi-layered pouch wrapper |
US9167835B2 (en) | 2008-12-30 | 2015-10-27 | Philip Morris Usa Inc. | Dissolvable films impregnated with encapsulated tobacco, tea, coffee, botanicals, and flavors for oral products |
US8863755B2 (en) | 2009-02-27 | 2014-10-21 | Philip Morris Usa Inc. | Controlled flavor release tobacco pouch products and methods of making |
US9167847B2 (en) | 2009-03-16 | 2015-10-27 | Philip Morris Usa Inc. | Production of coated tobacco particles suitable for usage in a smokeless tobacoo product |
US9687023B2 (en) * | 2009-10-09 | 2017-06-27 | Philip Morris Usa Inc. | Moist smokeless tobacco product for oral usage having on a portion of the outer surface at least one friction reducing strip that provides texture during use |
US8747562B2 (en) | 2009-10-09 | 2014-06-10 | Philip Morris Usa Inc. | Tobacco-free pouched product containing flavor beads providing immediate and long lasting flavor release |
US8539958B2 (en) | 2009-10-13 | 2013-09-24 | Philip Morris Usa Inc. | Oral moist smokeless tobacco products with net-structured gel coating and methods of making |
EP2529634B1 (en) * | 2010-01-28 | 2018-04-18 | Japan Tobacco, Inc. | Tobacco product with a hydrophobic wrapping material |
US10051884B2 (en) | 2010-03-26 | 2018-08-21 | Philip Morris Usa Inc. | Controlled release mentholated tobacco beads |
EP2558370B1 (en) | 2010-04-12 | 2017-04-05 | Altria Client Services LLC | Pouch product with improved seal and method |
US8241680B2 (en) | 2010-06-30 | 2012-08-14 | Rock Creek Pharmaceuticals, Inc. | Nutraceutical product containing anatabine and yerba maté |
US10028520B2 (en) | 2010-09-02 | 2018-07-24 | R.J. Reynolds Tobacco Company | Apparatus for manufacturing a smokeless tobacco product incorporating an object, and associated method |
US8931493B2 (en) | 2010-11-01 | 2015-01-13 | R.J. Reynolds Tobacco Co. | Smokeless tobacco products |
US9908670B2 (en) | 2011-01-31 | 2018-03-06 | American Snuff Company, Llc | Container for smokeless tobacco products |
SE535587C2 (en) | 2011-03-29 | 2012-10-02 | Chill Of Sweden Ab | Product containing a free nicotine salt and a non-water-soluble bag |
AU2012302257A1 (en) | 2011-08-29 | 2014-03-13 | Rcp Development, Inc. | Products for anti-inflammation support |
US10881132B2 (en) | 2011-12-14 | 2021-01-05 | R.J. Reynolds Tobacco Company | Smokeless tobacco product comprising effervescent composition |
US9420825B2 (en) | 2012-02-13 | 2016-08-23 | R.J. Reynolds Tobacco Company | Whitened tobacco composition |
DK2649888T3 (en) | 2012-04-10 | 2020-04-27 | Swedish Match North Europe Ab | Smokeless tobacco composition comprising non-tobacco fibers and a process for making them |
US20130292279A1 (en) | 2012-05-04 | 2013-11-07 | R.J. Reynolds Tobacco Company | Transparent moisture barrier coatings for containers |
US20130340773A1 (en) | 2012-06-22 | 2013-12-26 | R.J. Reynolds Tobacco Company | Composite tobacco-containing materials |
GB2504495A (en) | 2012-07-30 | 2014-02-05 | British American Tobacco Co | Fleece for smokeless tobacco pouch |
US9386800B2 (en) | 2012-09-21 | 2016-07-12 | R.J. Reynolds Tobacco Company | Fibrous composite tobacco-containing materials |
US9591875B2 (en) | 2012-09-21 | 2017-03-14 | R. J. Reynolds Tobacco Company | Fibrous composite tobacco-containing materials |
GB201220280D0 (en) * | 2012-11-12 | 2012-12-26 | British American Tobacco Co | Products including capsules, uses and preparation thereof |
CN102920013B (en) * | 2012-11-19 | 2015-02-11 | 湖南中烟工业有限责任公司 | Tobacco extractive microcapsule and preparation method thereof |
US20140255452A1 (en) | 2013-03-11 | 2014-09-11 | Niconovum Usa, Inc. | Method and apparatus for differentiating oral pouch products |
US11503853B2 (en) | 2013-09-09 | 2022-11-22 | R.J. Reynolds Tobacco Company | Smokeless tobacco composition incorporating a botanical material |
US10357054B2 (en) | 2013-10-16 | 2019-07-23 | R.J. Reynolds Tobacco Company | Smokeless tobacco pastille |
CN103783648B (en) * | 2014-02-21 | 2015-08-19 | 安徽中烟工业有限责任公司 | The sampling method of the process sample in a kind of beating and double roasting operation |
US11019840B2 (en) * | 2014-07-02 | 2021-06-01 | R.J. Reynolds Tobacco Company | Oral pouch products |
US10959456B2 (en) | 2014-09-12 | 2021-03-30 | R.J. Reynolds Tobacco Company | Nonwoven pouch comprising heat sealable binder fiber |
US20160157515A1 (en) | 2014-12-05 | 2016-06-09 | R.J. Reynolds Tobacco Company | Smokeless tobacco pouch |
US20160192703A1 (en) * | 2015-01-07 | 2016-07-07 | R.J. Reynolds Tobacco Company | Oral pouch products |
US10881133B2 (en) | 2015-04-16 | 2021-01-05 | R.J. Reynolds Tobacco Company | Tobacco-derived cellulosic sugar |
US9918492B2 (en) | 2015-05-14 | 2018-03-20 | R.J. Reynolds Tobacco Company | Treatment of tobacco |
US11147309B2 (en) | 2015-06-10 | 2021-10-19 | R.J. Reynolds Tobacco Company | Container for smokeless tobacco products comprising a pulp material and related packaged product assembly and method |
CN105116837B (en) * | 2015-07-13 | 2018-03-16 | 河北白沙烟草有限责任公司 | A kind of filament cutter automatic speed regulation control method and equipment based on material volume weight Cumulate algorithm |
US10499684B2 (en) | 2016-01-28 | 2019-12-10 | R.J. Reynolds Tobacco Company | Tobacco-derived flavorants |
US11154087B2 (en) | 2016-02-02 | 2021-10-26 | R.J. Reynolds Tobacco Company | Method for preparing flavorful compounds isolated from black liquor and products incorporating the flavorful compounds |
US11091446B2 (en) | 2017-03-24 | 2021-08-17 | R.J. Reynolds Tobacco Company | Methods of selectively forming substituted pyrazines |
US10470487B2 (en) | 2017-04-06 | 2019-11-12 | R.J. Reynolds Tobacco Company | Smoke treatment |
US10548347B2 (en) | 2018-02-23 | 2020-02-04 | American Snuff Company, Llc | Container for smokeless tobacco products |
DK3774570T3 (en) | 2018-04-13 | 2022-05-23 | Reynolds Tobacco Co R | LID FOR A CONTAINER FOR SMOKE-FREE TOBACCO PRODUCTS AND METHOD FOR MANUFACTURE OF SUCH A LID |
US20200196658A1 (en) | 2018-12-20 | 2020-06-25 | R.J. Reynolds Tobacco Company | Method for whitening tobacco |
US11213062B2 (en) | 2019-05-09 | 2022-01-04 | American Snuff Company | Stabilizer for moist snuff |
EP3979841B1 (en) * | 2019-06-05 | 2023-04-19 | Philip Morris Products S.A. | Nicotine composition, method for making and aerosol generating articles comprising such |
DK3773495T3 (en) * | 2019-06-07 | 2023-01-16 | Philip Morris Products Sa | COMPOSITION OF NICOTINE POUCH |
CN110384700A (en) * | 2019-09-03 | 2019-10-29 | 云南喜科科技有限公司 | A kind of composition synthesizing nicotine |
CA3150662A1 (en) | 2019-09-11 | 2021-03-18 | Michael Andrew Zawadzki | Alternative methods for whitening tobacco |
US12063953B2 (en) | 2019-09-11 | 2024-08-20 | Nicoventures Trading Limited | Method for whitening tobacco |
US11369131B2 (en) | 2019-09-13 | 2022-06-28 | Nicoventures Trading Limited | Method for whitening tobacco |
US20210169138A1 (en) | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Fibrous fleece material |
CA3159813A1 (en) | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Oral product with dissolvable component |
US11969502B2 (en) | 2019-12-09 | 2024-04-30 | Nicoventures Trading Limited | Oral products |
WO2021116842A1 (en) * | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Oral products with controlled release |
US11793230B2 (en) | 2019-12-09 | 2023-10-24 | Nicoventures Trading Limited | Oral products with improved binding of active ingredients |
MX2022006980A (en) | 2019-12-09 | 2022-08-25 | Nicoventures Trading Ltd | Pouched products with heat sealable binder. |
US11872231B2 (en) | 2019-12-09 | 2024-01-16 | Nicoventures Trading Limited | Moist oral product comprising an active ingredient |
US11617744B2 (en) | 2019-12-09 | 2023-04-04 | Nico Ventures Trading Limited | Moist oral compositions |
US11826462B2 (en) | 2019-12-09 | 2023-11-28 | Nicoventures Trading Limited | Oral product with sustained flavor release |
GB202006143D0 (en) * | 2020-04-27 | 2020-06-10 | Nonwovenn Ltd | Nonwoven fabric for oral pounched product, and methods of manufacturing a nonwoven fabric |
US11937626B2 (en) | 2020-09-04 | 2024-03-26 | Nicoventures Trading Limited | Method for whitening tobacco |
EP4284972A1 (en) | 2021-01-28 | 2023-12-06 | Nicoventures Trading Limited | Method for sealing pouches |
CA3238147A1 (en) | 2021-11-15 | 2023-05-19 | Christopher Keller | Products with enhanced sensory characteristics |
WO2023194959A1 (en) | 2022-04-06 | 2023-10-12 | Nicoventures Trading Limited | Pouched products with heat sealable binder |
US20240109697A1 (en) | 2022-10-03 | 2024-04-04 | Nicoventures Trading Limited | Sealing member for packaging |
WO2024074988A1 (en) | 2022-10-04 | 2024-04-11 | R. J. Reynolds Tobacco Company | Stackable arrangement of product containers and related method of stacking |
WO2024079696A1 (en) | 2022-10-14 | 2024-04-18 | Nicoventures Trading Limited | Apparatus and method for manufacturing and inspecting a pouched product or at least one object associated therewith |
WO2024079697A1 (en) | 2022-10-14 | 2024-04-18 | Nicoventures Trading Limited | Apparatus and method for manufacturing a pouched product |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1243507A (en) * | 1968-03-13 | 1971-08-18 | British Petroleum Co | Ultrafiltration separation process |
US3757798A (en) * | 1972-01-03 | 1973-09-11 | W Lambert | Method of reducing dependence on tobacco |
US4666991A (en) * | 1984-11-05 | 1987-05-19 | Sagami Chemical Research Center | Fluorine-containing graft copolymer and adhesive and composite membrane made thereof |
DK169616B1 (en) * | 1986-08-27 | 1994-12-27 | Dow Danmark | Permeable, porous, polymer-treated plastic membrane with hydrophilic character, processes for their preparation and use thereof |
US4975270A (en) * | 1987-04-21 | 1990-12-04 | Nabisco Brands, Inc. | Elastomer encased active ingredients |
JPH01108966A (en) * | 1987-10-22 | 1989-04-26 | Kowa Display:Kk | Snuff |
US4941484A (en) * | 1989-05-30 | 1990-07-17 | R. J. Reynolds Tobacco Company | Tobacco processing |
US5069231A (en) * | 1989-07-12 | 1991-12-03 | International Flavors & Fragrances Inc. | Method for imparting functional ingredients, functional ingredient-imparting articles and methods for preparation and use thereof |
US5824334A (en) * | 1989-09-05 | 1998-10-20 | University Of Utah Research Foundation | Tobacco substitute |
EP0540623B1 (en) * | 1990-07-23 | 1994-09-14 | Alza Corporation | Oral osmotic device for delivering nicotine |
US5403595A (en) * | 1991-05-07 | 1995-04-04 | Dynagen, Inc. | Controlled, sustained release delivery system for smoking cessation |
US5372149A (en) * | 1992-03-25 | 1994-12-13 | Roth; David S. | Sterilization process in the manufacturing of snuff |
US5465739A (en) * | 1992-04-15 | 1995-11-14 | R. J. Reynolds Tobacco Company | Cigarette and cigarette filter element therefor |
US5346734A (en) * | 1993-04-16 | 1994-09-13 | Bethanie K. Wydick | Perforated latex oral pouch for loose snuff |
US5387416A (en) * | 1993-07-23 | 1995-02-07 | R. J. Reynolds Tobacco Company | Tobacco composition |
IE72523B1 (en) * | 1994-03-10 | 1997-04-23 | Elan Med Tech | Nicotine oral delivery device |
AU7662796A (en) * | 1995-10-11 | 1997-04-30 | Dedric M. Derr | System and method for protecting oral tissues from smokeless tobacco |
-
2002
- 2002-12-17 EP EP02795287A patent/EP1458252B1/en not_active Expired - Lifetime
- 2002-12-17 DE DE60224832T patent/DE60224832T2/en not_active Expired - Lifetime
- 2002-12-17 US US10/499,552 patent/US20050061339A1/en not_active Abandoned
- 2002-12-17 AU AU2002360097A patent/AU2002360097A1/en not_active Abandoned
- 2002-12-17 AT AT02795287T patent/ATE384450T1/en not_active IP Right Cessation
- 2002-12-17 DK DK02795287T patent/DK1458252T3/en active
- 2002-12-17 WO PCT/EP2002/014853 patent/WO2003053175A2/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008038556A1 (en) * | 2008-06-26 | 2009-12-31 | Eswegee Vliesstoff Gmbh | Nonwoven fabric for use as a moisture-permeable, microporous semi-luxury packaging material |
Also Published As
Publication number | Publication date |
---|---|
US20050061339A1 (en) | 2005-03-24 |
AU2002360097A8 (en) | 2003-07-09 |
DE60224832T2 (en) | 2009-01-22 |
DE60224832D1 (en) | 2008-03-13 |
EP1458252A2 (en) | 2004-09-22 |
DK1458252T3 (en) | 2008-05-13 |
WO2003053175A3 (en) | 2003-10-09 |
ATE384450T1 (en) | 2008-02-15 |
AU2002360097A1 (en) | 2003-07-09 |
WO2003053175A2 (en) | 2003-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1458252B1 (en) | Tobacco and/or tobacco in combination with tobacco substitute composition for use as a snuff in the oral cavity | |
JP5694645B2 (en) | Improved snuff composition | |
EP1617823B1 (en) | A pouch comprising a nicotine composition for transmucosal delivery | |
US8846075B2 (en) | Composition material for transmucosal delivery | |
DK2691096T3 (en) | Bag containing free nicotine in salt form | |
ES2321721T3 (en) | NICOTINE FORMULATIONS AND USE OF THE SAME. | |
EP3833315B1 (en) | A pouch product suitable for application in an oral cavity | |
US20050034738A1 (en) | Chewing tobacco substitute containing nicotine | |
EP3993646B1 (en) | An oral pouched nicotine product including a filling material comprising nicotine-containing particles | |
WO2021099571A1 (en) | An oral pouched nicotine product including a filling material comprising nicotine particles | |
CN107744174A (en) | For the preparation and part being added in tobacco product | |
CA2868445C (en) | Nicotine formulation | |
EP3868222A1 (en) | Smokeless article | |
US20060112965A1 (en) | Chewing tobacco substitute containing cotinine | |
EP4106556A1 (en) | Smokeless article | |
EP3868223A1 (en) | Smokeless article | |
RU2779390C1 (en) | Packaged product suitable for application in the oral cavity | |
US20220386685A1 (en) | Smokeless article |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040721 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SPEGEL, CHRISTER Inventor name: HANSSON, HENRI Inventor name: HOVGAARD, LARS |
|
RTI1 | Title (correction) |
Free format text: TOBACCO AND/OR TOBACCO IN COMBINATION WITH TOBACCO SUBSTITUTE COMPOSITION FOR USE AS A SNUFF IN THE ORAL CAVITY |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60224832 Country of ref document: DE Date of ref document: 20080313 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Ref country code: SE Ref legal event code: TRGR |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080123 Ref country code: LI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080123 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080504 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080123 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080423 |
|
ET | Fr: translation filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080623 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080123 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080123 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080123 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080123 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20081024 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081231 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081217 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081217 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080424 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20131230 Year of fee payment: 12 Ref country code: DK Payment date: 20131230 Year of fee payment: 12 Ref country code: GB Payment date: 20131230 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FI Payment date: 20131230 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20140102 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20131231 Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60224832 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20141231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141218 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141217 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20141217 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20150831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141217 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141231 |